Teva Pharmaceutical (TEVA) Tops Q4 EPS by 2c; Reaffirms Outlook
Tweet Send to a Friend
Teva Pharmaceutical (NYSE: TEVA) reported Q4 EPS of $1.42, $0.16 better than the analyst estimate of $1.40. Revenue for the ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
